These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23307169)

  • 1. Gene therapy for heart failure: where do we stand?
    Naim C; Yerevanian A; Hajjar RJ
    Curr Cardiol Rep; 2013 Feb; 15(2):333. PubMed ID: 23307169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of gene therapy as a treatment for heart failure.
    Hajjar RJ
    J Clin Invest; 2013 Jan; 123(1):53-61. PubMed ID: 23281410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for heart failure.
    Tilemann L; Ishikawa K; Weber T; Hajjar RJ
    Circ Res; 2012 Mar; 110(5):777-93. PubMed ID: 22383712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac gene therapy with SERCA2a: from bench to bedside.
    Gwathmey JK; Yerevanian AI; Hajjar RJ
    J Mol Cell Cardiol; 2011 May; 50(5):803-12. PubMed ID: 21093451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.
    Hulot JS; Senyei G; Hajjar RJ
    Gene Ther; 2012 Jun; 19(6):596-9. PubMed ID: 22673498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.
    Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R
    Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
    Papolos A; Frishman WH
    Cardiol Rev; 2013; 21(3):151-4. PubMed ID: 23568057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for heart failure.
    Greenberg B
    J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
    Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
    JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
    Gwathmey JK; Yerevanian A; Hajjar RJ
    Hum Gene Ther; 2013 Nov; 24(11):937-47. PubMed ID: 24164241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescuing the failing heart by targeted gene transfer.
    Kawase Y; Ladage D; Hajjar RJ
    J Am Coll Cardiol; 2011 Mar; 57(10):1169-80. PubMed ID: 21371634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for the treatment of heart failure: promise postponed.
    Hulot JS; Ishikawa K; Hajjar RJ
    Eur Heart J; 2016 Jun; 37(21):1651-8. PubMed ID: 26922809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
    Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy in heart failure.
    Vinge LE; Raake PW; Koch WJ
    Circ Res; 2008 Jun; 102(12):1458-70. PubMed ID: 18566312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.
    del Monte F; Williams E; Lebeche D; Schmidt U; Rosenzweig A; Gwathmey JK; Lewandowski ED; Hajjar RJ
    Circulation; 2001 Sep; 104(12):1424-9. PubMed ID: 11560860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.
    Lipskaia L; Chemaly ER; Hadri L; Lompre AM; Hajjar RJ
    Expert Opin Biol Ther; 2010 Jan; 10(1):29-41. PubMed ID: 20078230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets in heart failure gene therapy: current controversies and translational perspectives.
    Kairouz V; Lipskaia L; Hajjar RJ; Chemaly ER
    Ann N Y Acad Sci; 2012 Apr; 1254():42-50. PubMed ID: 22548568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-associated virus-mediated gene therapy in cardiovascular disease.
    Hammoudi N; Ishikawa K; Hajjar RJ
    Curr Opin Cardiol; 2015 May; 30(3):228-34. PubMed ID: 25783685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in gene therapy for heart failure.
    Fish KM; Ishikawa K
    Discov Med; 2015 Apr; 19(105):285-91. PubMed ID: 25977191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in gene therapy for heart failure.
    Yerevanian A; Yerevanian A; Hajjar RJ
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):95-106. PubMed ID: 23921315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.